(To see other currencies, click on price)
MORE ABOUT THIS BOOK
Main description:
Insulin–like growth factor (IGF–1) is an anabolic effector hormone that, in recent years, has been linked with several types of malignancy. These include prostate, ovarian and colon cancers. However, the nature of this relationship with cancer is uncertain and the linkage itself is controversial.
The IGF–1 receptors and signalling pathways are similar to those of insulin, even though the biological actions of these hormones are different. Because of the similarities, insulin is often also considered when the link between IGF–1 and cancer is discussed.
The clinical use of long–term growth hormone treatment is increasing and such treatment leads to raised IGF–1 levels. Increased insulin levels are also more common as the prevalence of insulin resistance, which frequently presages obesity and/or type 2 diabetes, increases in the population. Therefore, a careful discussion of the role of IGF–1 and insulin in various cancers is urgently needed. This book examines these issues in detail. It features contributions from the leading scientists and clinicians in the field and should prove essential reading for anyone with a clinical interest in insulin and the IGFs.
Back cover:
Insulin–like growth factor (IGF–1) is an anabolic effector hormone that, in recent years, has been linked with several types of malignancy. These include prostate, ovarian and colon cancers. However, the nature of this relationship with cancer is uncertain and the linkage itself is controversial.
The IGF–1 receptors and signalling pathways are similar to those of insulin, even though the biological actions of these hormones are different. Because of the similarities, insulin is often also considered when the link between IGF–1 and cancer is discussed.
The clinical use of long–term growth hormone treatment is increasing and such treatment leads to raised IGF–1 levels. Increased insulin levels are also more common as the prevalence of insulin resistance, which frequently presages obesity and/or type 2 diabetes, increases in the population. Therefore, a careful discussion of the role of IGF–1 and insulin in various cancers is urgently needed. This book examines these issues in detail. It features contributions from the leading scientists and clinicians in the field and should prove essential reading for anyone with a clinical interest in insulin and the IGFs.
Contents:
Chair′s Introduction (Leroith).
Circulating IGF–I and its role in cancer: lessons from the IGF–1 gene–deletion (LID) mouse (Yakar et al).
Physiology of the IGF system (Holly).
Molecular basis of insulin action (Zick).
IGF–1 and insulin as growth hormones (Laron).
Insulin–like growth factors and neoplasia (Pollak).
Loss of IGF2 imprinting: mechanisms and consequences (Ohlsson).
Insulin and IGF–1 receptor trafficking and sginalling (Foti et al).
The mTOR/S6K signalling pathway: the role of the TSC1/2 tumour suppressor complex and the proto–oncogene Rheb (Nobukini and Thomas).
Structural biology of insulin and IGF–1 receptors (De Meyts et al).
Genetic blockade of the insulin–like growth factor–I receptor for human malignancy (Adachi et al).
IGF–1 and prostate cancer (Roberts Jr.).
IGF–1 and breast cancer (Lonning and Helle).
IGFBPs and cancer (Fang et al).
The IGF receptor as anti–cancer treatment target (Macaulay).
Nutrition, insulin, IGF–1 metabolism and cancer risk: a summary of epidemiological evidence (Kaaks).
Final discussion.
Index of contributors.
Subject index.
PRODUCT DETAILS
Publisher: John Wiley & Sons Ltd (Wiley–Blackwell)
Publication date: October, 2008
Pages: 288
Dimensions: 167.00 x 238.00 x 18.00
Weight: 600g
Availability: Not available (reason unspecified)
Subcategories: Diseases and Disorders
From the same series
